Abstract
Effective immunosuppressive regimens to prevent the development of graft-versus-host disease (GVHD) are essential to the success of allogeneic hematopoietic cell transplantation (HCT). After revolutionizing haploidentical transplantation, post-transplantation cyclophosphamide (PTCy) is now being evaluated for HCT performed from related and unrelated donors. In this setting, 2 recent randomized studies have demonstrated lower rates of GVHD and superior GVHD-free, relapse-free survival with PTCy compared with conventional GVHD prophylaxis. The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) is currently conducting a large, randomized phase III, multicenter trial (BMT CTN 1703) comparing PTCy/tacrolimus/mycophenolate mofetil to tacrolimus/methotrexate as GVHD prophylaxis regimens in reduced-intensity allogeneic HCT. Here we review the ongoing study, highlight its importance to the field, and explore the possible implications of its results on clinical practice.
Original language | English (US) |
---|---|
Pages (from-to) | e305-e308 |
Journal | Biology of Blood and Marrow Transplantation |
Volume | 26 |
Issue number | 12 |
DOIs |
|
State | Published - Dec 2020 |
Keywords
- Allogeneic hematopoietic cell transplantation
- Graft-versus-host disease
- Prophylaxis
ASJC Scopus subject areas
- Hematology
- Transplantation